A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP

A Study to Evaluate the Impact of Mosunetuzumab Consolidation for Older Patients With Diffuse Large B-cell Lymphoma (DLBCL) Who Have Detectable Amounts of ctDNA (Circulating Tumor DNA) at the End of Treatment With Pola-R-mini-CHP is a phase 2 interventional study registered as NCT06828991 by Danielle Wallace, with 40 participants planned, started 2025-09-04 and due to reach its primary completion in 2029-04-01. Interventions recorded: Mosunetuzumab, ClonoSEQ. Conditions recorded: Diffuse Large B-Cell Lymphoma (DLBCL).

Linked to the drug clonoSEQ because the registry names it among its interventions and Diffuse large B-cell lymphoma among its conditions. Registry record only: no result has been read by an editor.